In Vitro Evaluations on Canine Monocyte-derived Dendritic Cells of a Nanoparticles Delivery System for Vaccine Antigen Against Echinococcus Granulosus

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Feb 27

PMID 32101539

Citations 6

Authors

Nadege Milhau

Eyad Almouazen

Sylvie Bouteille

Imene Hellel-Bourtal

Samira Azzouz-Maache

Uruguaysito Benavides

Anne-Francoise Petavy

Thierry Marchal

Affiliations

Soon will be listed here.

Abstract

Since dogs play a central role in the contamination of humans and livestock with Echinococcus granulosus, the development of an effective vaccine for dogs is essential to control the disease caused by this parasite. For this purpose, a formulation based on biodegradable polymeric nanoparticles (NPs) as delivery system of recombinant Echinococcus granulosus antigen (tropomyosin EgTrp) adjuved with monophosphoryl lipid A (MPLA) has been developed. The obtained nanoparticles had a size of approximately 200 nm in diameter into which the antigen was correctly preserved and encapsulated. The efficiency of this system to deliver the antigen was evaluated in vitro on canine monocyte-derived dendritic cells (cMoDCs) generated from peripheral blood monocytes. After 48 h of contact between the formulations and cMoDCs, we observed no toxic effect on the cells but a strong internalization of the NPs, probably through different pathways depending on the presence or not of MPLA. An evaluation of cMoDCs activation by flow cytometry showed a stronger expression of CD80, CD86, CD40 and MHCII by cells treated with any of the tested formulations or with LPS (positive control) in comparison to cells treated with PBS (negative control). A higher activation was observed for cells challenged with EgTrp-NPs-MPLA compared to EgTrp alone. Formulations with MPLA, even at low ratio of MPLA, give better results than formulations without MPLA, proving the importance of the adjuvant in the nanoparticles structure. Moreover, autologous T CD4+ cell proliferation observed in presence of cMoDCs challenged with EgTrp-NPs-MPLA was higher than those observed after challenged with EgTrp alone (p<0.05). These first results suggest that our formulation could be used as an antigen delivery system to targeting canine dendritic cells in the course of Echinococcus granulosus vaccine development.

Citing Articles

Characterization of polarization states of canine monocyte derived macrophages.

Lyu Q, Veldhuizen E, Ludwig I, Rutten V, van Eden W, Sijts A PLoS One. 2023; 18(11):e0292757.

PMID: 37939066 PMC: 10631683. DOI: 10.1371/journal.pone.0292757.

The Antimicrobial Applications of Nanoparticles in Veterinary Medicine: A Comprehensive Review.

Rodrigues M, Pinto P, Dias R, Biscoto G, Salvato L, Millan R Antibiotics (Basel). 2023; 12(6).

PMID: 37370277 PMC: 10295505. DOI: 10.3390/antibiotics12060958.

Design and functional preliminary investigation of recombinant antigen EgG1Y162-EgG1Y162 against .

Zhou Y, Zhao S, Li Y, Yu M, Zheng J, Gong Q Open Life Sci. 2023; 18(1):20220558.

PMID: 36941829 PMC: 10024343. DOI: 10.1515/biol-2022-0558.

The Recombinant g.P29-Mediated miR-126a-5p Promotes the Differentiation of Mouse Naive CD4 T Cells DLK1-Mediated Notch1 Signal Pathway.

Du X, Zhu M, Zhang T, Wang C, Tao J, Yang S Front Immunol. 2022; 13:773276.

PMID: 35211114 PMC: 8861942. DOI: 10.3389/fimmu.2022.773276.

Promising Technologies in the Field of Helminth Vaccines.

Perera D, Ndao M Front Immunol. 2021; 12:711650.

PMID: 34489961 PMC: 8418310. DOI: 10.3389/fimmu.2021.711650.

References

Petavy A, Hormaeche C, Lahmar S, Ouhelli H, Chabalgoity A, Marchal T . An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis. 2008; 2(1):e125. PMC: 2217674. DOI: 10.1371/journal.pntd.0000125. View

Reddy S, Swartz M, Hubbell J . Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006; 27(12):573-9. DOI: 10.1016/j.it.2006.10.005. View

Hunsawong T, Sunintaboon P, Warit S, Thaisomboonsuk B, Jarman R, Yoon I . A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice. Vaccine. 2015; 33(14):1702-10. DOI: 10.1016/j.vaccine.2015.02.016. View

Xiang S, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram P . Pathogen recognition and development of particulate vaccines: does size matter?. Methods. 2006; 40(1):1-9. DOI: 10.1016/j.ymeth.2006.05.016. View

Zhao L, Seth A, Wibowo N, Zhao C, Mitter N, Yu C . Nanoparticle vaccines. Vaccine. 2013; 32(3):327-37. DOI: 10.1016/j.vaccine.2013.11.069. View

Heath D, Robinson C, Shakes T, Huang Y, Gulnur T, Shi B . Vaccination of bovines against Echinococcus granulosus (cystic echinococcosis). Vaccine. 2012; 30(20):3076-81. DOI: 10.1016/j.vaccine.2012.02.073. View

Gregory A, Titball R, Williamson D . Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013; 3:13. PMC: 3607064. DOI: 10.3389/fcimb.2013.00013. View

Moro P, Schantz P . Echinococcosis: a review. Int J Infect Dis. 2008; 13(2):125-33. DOI: 10.1016/j.ijid.2008.03.037. View

Grabowski N, Hillaireau H, Vergnaud J, Santiago L, Kerdine-Romer S, Pallardy M . Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. Int J Pharm. 2013; 454(2):686-94. DOI: 10.1016/j.ijpharm.2013.05.025. View

10.

Margaroni M, Agallou M, Kontonikola K, Karidi K, Kammona O, Kiparissides C . PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation. Eur J Pharm Biopharm. 2016; 105:18-31. DOI: 10.1016/j.ejpb.2016.05.018. View

11.

Pan W, Chen D, Lu Y, Xu H, Hao W, Zhang Y . Genetic diversity and phylogenetic analysis of EG95 sequences of Echinococcus granulosus: Implications for EG95 vaccine application. Asian Pac J Trop Med. 2017; 10(5):524-527. DOI: 10.1016/j.apjtm.2017.05.011. View

12.

Sehgal K, Dhodapkar K, Dhodapkar M . Targeting human dendritic cells in situ to improve vaccines. Immunol Lett. 2014; 162(1 Pt A):59-67. PMC: 4506641. DOI: 10.1016/j.imlet.2014.07.004. View

13.

Ibisch C, Pradal G, Bach J, Lieubeau B . Functional canine dendritic cells can be generated in vitro from peripheral blood mononuclear cells and contain a cytoplasmic ultrastructural marker. J Immunol Methods. 2005; 298(1-2):175-82. DOI: 10.1016/j.jim.2005.02.001. View

14.

Tyler B, Gullotti D, Mangraviti A, Utsuki T, Brem H . Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv Drug Deliv Rev. 2016; 107:163-175. DOI: 10.1016/j.addr.2016.06.018. View

15.

Lightowlers M, Lawrence S, Gauci C, Young J, Ralston M, MAAS D . Vaccination against hydatidosis using a defined recombinant antigen. Parasite Immunol. 1996; 18(9):457-62. DOI: 10.1111/j.1365-3024.1996.tb01029.x. View

16.

Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M . Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol. 2007; 178(5):2979-86. DOI: 10.4049/jimmunol.178.5.2979. View

17.

Moon J, Suh H, Polhemus M, Ockenhouse C, Yadava A, Irvine D . Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One. 2012; 7(2):e31472. PMC: 3273465. DOI: 10.1371/journal.pone.0031472. View

18.

Wang Y, Chi K, Liao K, Liu C, Cheng C, Lin Y . Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation. Can J Vet Res. 2007; 71(3):165-74. PMC: 1899861. View

19.

Elamanchili P, Diwan M, Cao M, Samuel J . Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004; 22(19):2406-12. DOI: 10.1016/j.vaccine.2003.12.032. View

20.

Sarti F, Perera G, Hintzen F, Kotti K, Karageorgiou V, Kammona O . In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials. 2011; 32(16):4052-7. DOI: 10.1016/j.biomaterials.2011.02.011. View